ALMS

NASDAQ 已收盘

Alumis

4.33 USD
▼-0.07-1.48%
盘后 4.50 +3.93%
2026-11-19
市值
$514.09M
市盈率
—
EPS
-3.48
股息率
—
52 周区间
4.22 – 31.35
成交量
1.48M
Beta
-0.27
目标价
25.38
52W 低 4.2252W 高 31.35
价格走势

公司简介

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid e...

关联新闻